-
公开(公告)号：US09969812B2
公开(公告)日：2018-05-15
申请号：US15382821
申请日：2016-12-19
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: A61K39/395 , C07K16/28 , C07K16/30 , C07K14/705 , C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , C12N9/14 , C07K14/71 , A61K39/00
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
-
公开(公告)号：US20190388420A1
公开(公告)日：2019-12-26
申请号：US16465277
申请日：2018-02-06
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoichi Ozawa , Yusaku Hori , Kazuhiko Yamada , Hiroshi Kamiyama , Masahiro Matsuki
IPC: A61K31/4985 , A61P35/00
Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
-
公开(公告)号：US09527921B2
公开(公告)日：2016-12-27
申请号：US15098869
申请日：2016-04-14
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: A61K39/395 , C07K16/32 , A61K33/24 , A61K31/47 , A61K31/337 , C07K16/28 , C07K16/30 , C07K14/705 , C07K14/71 , A61K39/00
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
Abstract translation: 本发明提供了可能对人Notch4具有中和活性的抗人Notch4抗体或Notch4结合片段，以及包含与活性成分相同的药物组合物。 本发明人获得了对人Notch4具有高中和活性和结合亲和力的小鼠抗人Notch4抗体，并确定了小鼠抗人Notch4抗体的互补决定区（CDR）序列。 这使得能够生产包含重链和轻链的可变区以及小鼠抗人Notch4抗体的CDR序列的人源化抗体。
-
Patent Agency Ranking
公开(公告)号：US11925639B2
公开(公告)日：2024-03-12
申请号：US16465277
申请日：2018-02-06
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoichi Ozawa , Yusaku Hori , Kazuhiko Yamada , Hiroshi Kamiyama , Masahiro Matsuki
IPC: A61K31/4985 , A61K31/53 , A61P35/00
CPC classification number: A61K31/4985 , A61K31/53 , A61P35/00
Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
-
公开(公告)号：US11369623B2
公开(公告)日：2022-06-28
申请号：US15736561
申请日：2016-06-15
Applicant: PRISM Pharma Co., Ltd. , EISAI R&D MANAGEMENT CO., LTD.
Inventor： Takenao Odagami , Hiroyuki Kouji , Yoichi Ozawa , Yusaku Hori
IPC: A61K31/675 , A61K45/06 , A61K39/395 , A61K31/53 , A61K31/519 , C07K16/28 , A61P35/00
Abstract: The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone.
-
公开(公告)号：US20160347858A1
公开(公告)日：2016-12-01
申请号：US15098869
申请日：2016-04-14
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino
IPC: C07K16/32 , A61K31/337 , A61K31/47 , A61K39/395 , A61K33/24
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
Abstract translation: 本发明提供了可能对人Notch4具有中和活性的抗人Notch4抗体或Notch4结合片段，以及包含与活性成分相同的药物组合物。 本发明人获得了对人Notch4具有高中和活性和结合亲和力的小鼠抗人Notch4抗体，并确定了所述小鼠抗人Notch4抗体的互补决定区（CDR）序列。 这使得能够产生包含重链和轻链的可变区以及所述小鼠抗人Notch4抗体的CDR序列的人源化抗体。
-
公开(公告)号：US20180185395A1
公开(公告)日：2018-07-05
申请号：US15736561
申请日：2016-06-15
Applicant: PRISM Pharma Co., Ltd. , EISAI R&D MANAGEMENT CO., LTD.
Inventor： Takenao Odagami , Hiroyuki Kouji , Yoichi Ozawa , Yusaku Hori
IPC: A61K31/675 , A61P35/00 , A61K39/395
CPC classification number: A61K31/675 , A61K31/519 , A61K31/53 , A61K39/395 , A61K39/3955 , A61K45/06 , A61P35/00
Abstract: The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone.
-
公开(公告)号：US20170096493A1
公开(公告)日：2017-04-06
申请号：US15382821
申请日：2016-12-19
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: C07K16/32 , A61K31/337 , A61K31/47 , A61K39/395 , A61K33/24
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.022 seconds)
